Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Parents want to do the best for their children, especially when they’re not feeling well. That often means giving liquid, over-the-counter (OTC) medications when they have a cold, fever or the flu. But even the best intentions can go wrong when it comes to dosing children’s OTC medicines.
OTC cough and cold medicines are safe and effective when used as directed – this includes always giving your child the precise, recommended dose. When it’s late at night and your child is sick, it may seem easier to reach for whatever is nearby, like a kitchen spoon, instead of taking the time to find the right dosing cup or syringe that came with the medicine. While 63 percent of parents surveyed say they prefer milliliter dosing devices to measure their children’s liquid medicine, 8 out of 10 parents* have given the wrong dose of liquid medicine to their child by accident.
To view the multimedia release go to:
https://www.multivu.com/players/English/8171651-chpa-educational-foundation-know-your-otcs/
GetWellNetwork®, the health care technology company that pioneered Interactive Patient Care™, introduced today a model for enhanced patient and family engagement that mirrors the fundamentals of precision medicine. Supported by The Patient’s Platform™ — a cross-continuum suite of integrated solutions, tools and strategies — Precision Engagement™ delivers uniquely personalized care guided by a person’s ability to take an active role in their health journey.
To view the multimedia release go to:
https://www.multivu.com/players/English/8151751-getwellnetwork-precision-engagement-the-patient-platform/
Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8295651-cancer-treatment-centers-of-america-foundation-medicine-precision-cancer-treatment/
In observance of World Arthritis Day, the Arthritis Foundation is calling on Americans to “Do Blue” on Tues., Oct. 12. From dressing head to toe with blue (hair) dos to blue shoes – and everything in between – to lighting up national monuments in blue, the effort aims to raise awareness of arthritis in all its forms and to urge the nation and individuals to take action to reduce the impact of the most common cause of disability in the U.S.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/46624/
Duchesnay USA launched a new online video series today about pregnancy health and morning sickness, which many don’t know is a medical condition called Nausea and Vomiting of Pregnancy (NVP). The series, entitled Navigating Morning Sickness, premiered with three videos about pregnancy nutrition, medication safety and the potential impact of NVP on a pregnant woman’s life. Additional new videos will be released throughout November and December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64373-duchesnay-usa-online-video-series-pregnancy-morning-sickness
People in the UK, who currently have significantly poorer access to cancer medicines compared to those in Europei, could soon be gaining access to life saving cancer treatments which are currently not available on the NHS, with the launch of the Cancer Drugs Fund. The interim funding of £50 million for cancer drugs made available today is ahead of the introduction of a longer term Cancer Drugs Fund of £600 million from 2011-2014.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/wishingwall/46284/
Medical researchers are making unprecedented progress into understanding why women suffer disproportionately from a number of diseases. Those insights are providing information to help develop medicines to attack diseases such as osteoporosis, multiple sclerosis, depression, rheumatoid arthritis and age-related macular degeneration, all of which affect more women than men.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/50270/
